- Home
- NTRB vs BNTC Comparison
NTRB vs BNTC Comparison
Compare NTRB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- BNTC
- Stock Information
- Founded
- NTRB 2016
- BNTC 1995
- Country
- NTRB United States
- BNTC United States
- Employees
- NTRB N/A
- BNTC N/A
- Industry
- NTRB Industrial Specialties
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- BNTC Health Care
- Exchange
- NTRB Nasdaq
- BNTC Nasdaq
- Market Cap
- NTRB 59.1M
- BNTC 366.6M
- IPO Year
- NTRB N/A
- BNTC N/A
- Fundamental
- Price
- NTRB $10.72
- BNTC $12.74
- Analyst Decision
- NTRB Buy
- BNTC Strong Buy
- Analyst Count
- NTRB 1
- BNTC 6
- Target Price
- NTRB $13.00
- BNTC $23.83
- AVG Volume (30 Days)
- NTRB 115.7K
- BNTC 219.6K
- Earning Date
- NTRB 05-30-2025
- BNTC 05-14-2025
- Dividend Yield
- NTRB N/A
- BNTC N/A
- EPS Growth
- NTRB N/A
- BNTC N/A
- EPS
- NTRB N/A
- BNTC N/A
- Revenue
- NTRB $2,398,437.00
- BNTC N/A
- Revenue This Year
- NTRB $560.75
- BNTC N/A
- Revenue Next Year
- NTRB $588.39
- BNTC N/A
- P/E Ratio
- NTRB N/A
- BNTC N/A
- Revenue Growth
- NTRB 18.92
- BNTC N/A
- 52 Week Low
- NTRB $3.72
- BNTC $7.05
- 52 Week High
- NTRB $11.78
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- NTRB 81.37
- BNTC 40.67
- Support Level
- NTRB $7.52
- BNTC $10.91
- Resistance Level
- NTRB $8.41
- BNTC $12.74
- Average True Range (ATR)
- NTRB 0.61
- BNTC 1.39
- MACD
- NTRB 0.14
- BNTC -0.41
- Stochastic Oscillator
- NTRB 79.51
- BNTC 29.56
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.